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In early bone marrow transplantation, the cells
given were thought to be simple replacements of
diseased cells after myeloablative therapies. Today
human cell populations are often used as agents of
therapy. As the uses and cell varieties have multiplied,
so has the need grown for a labeling system that works
both inside institutions as well as between widely
separated sites of collection and infusion.
The pioneers in cell therapy were Nobel Prize
winner E. Donnall Thomas and colleagues.1,2 These
bone marrow transplanters reasoned that if the bone
marrow was diseased with leukemia, and an HLA-
matched sibling could be found, the diseased bone
marrow could be eradicated by total body irradiation
and replaced with donated, matched, healthy bone
marrow. Their success in the late 1970s was a
phenomenal innovation for treating a disease that had
been commonly fatal. The work was highly experi-
mental, and the bone marrow product was usually
labeled simply with the name of the donor and that of
the patient for whom it was intended. Distance, time,
and processing were not major factors. The matched
sibling was brought to the place where the patient was
being treated, the cells were collected at that site, and
the transplant product was given fresh with minimal
processing.
Further expansion of cell therapy soon brought
new labeling requirements. In the early 1980s,
oncologists at the University of Nebraska reasoned that
if they could get a reduced-disease autologous bone
marrow (or later, peripheral blood that was likely to
contain engrafting bone marrow cells), they could give
the patient the same kind of high-dose chemotherapy
that the allogeneic transplant patients were receiving
and achieve a similar improvement or cure.3,4 Because
the patient was the donor, there were no problems
with finding a match or with graft-versus-host disease.
This simplicity, however, led to a more complex
labeling and tracking situation. The cellular products
were collected, processed, and frozen for the patient’s
future use in the same storage space with other
patients’ grafts. The labeling consisted mainly of the
patient’s name and Social Security or hospital number.
Because multiple collections of cells from each patient
had to be made over time, there was a proliferation of
cells to be frozen and stored together. Sometimes cells
from patients with similar names were mixed up.
When blood centers began to collect apheresis
products for transplantation, it was their practice to put
unit numbers on the label in addition to the autologous
patient information. These unique numbers allowed
the centers to use their regular routine for typing and
infectious disease testing. As automation in blood
banking progressed, centers started using bar-coded
numbers.
The success of autologous and related donor bone
marrow transplantation led to an expanded search for
donors. The related, matched-sibling approach could
serve only a small number of patients; only about 30
percent of patients had an HLA-matched sibling. In
1987, the National Marrow Donor Program (NMDP)
began to make HLA matches between volunteer
donors and patients for unrelated bone marrow
transplantation.5 The labeling problems were now
magnified. Cell products had to be collected and
shipped, often across countries and continents, yet
donors were promised anonymity. The NMDP
constructed a system in which a unique number was
handwritten on the label and the label was placed on
the product immediately after collection. The
information connecting the number to the donor and
to the matched patient was held by the NMDP.
The limitations of handwritten numbers soon
became apparent. Many laboratories around the world
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discovered that the way numbers are written,
especially the numbers 1 and 7, can be very different
and very difficult to read. Fortunately, because there
were seldom multiple products traveling to any one
location at the same time, and because each product
was transported by a courier, this did not usually pose
a problem.
Purpose of Labeling System
A labeling system has several essential tasks. These
include the ability to:
• name and uniquely identify each product,
• state the contents (other than the product) and
conditions of storage, and
• state the status of the product, namely to
– state whether the product is fully screened and
tested for allogeneic use or is for autologous
use only, and
– state other circumstances limiting use, includ-
ing donor ineligibility, as determined by the
FDA.
A labeling system should also include:
• standard names for standard products,
• a machine-readable labeling process, recognized
worldwide, that is also eye-readable (allowing
maximum safety and control of the process
where computerized management is possible,
but not leaving out locations that do not have
access to those sophisticated systems), and
• labels that meet FDA requirements (at least in the
United States).
Unique electronically readable identifiers can be
incorporated into data systems for continuity of
product identity through processing. These same data
systems can be accepted into patient charts and
electronic identification systems in laboratories and
clinics so there can be no inadvertent substitution of
the wrong product at the time of shipping or infusion.
Current thinking among FDA speakers is that cell
therapy products, when they are more than minimally
manipulated or are from unrelated donors (are other
than autologous or related products), should be
approved by the FDA as biologic products. Thus they
would require either an FDA-approved investigational
new drug application or a biological product
application. The FDA published a rule in February
2004 that human drug and biologic products would be
required to be labeled with a National Drug Code
(NDC) number (21 CFR 201.05). The final rule requires
that product labels must have a linear bar code that
contains, at a minimum, the drug’s NDC number. The
rule also requires machine-readable information on
blood and blood component labels. In direct questions
to FDA officials concerning the applicability of this rule
to cell therapy products, they confirmed that this
requirement would also apply to cell therapy products.
Product Names
In the pioneer days of bone marrow transplan-
tation, the collected early progenitor cells were called
hematopoietic stem cells, whether they came from
bone marrow or from peripheral blood.Product names
were quite freeform in those days, but usually
contained the name of the source material, such as
bone marrow or peripheral blood by apheresis, and the
designation stem cells. Sometimes this designation was
more hopeful than factual.
Culturing of colony-forming units was introduced
in research laboratories in the late 1980s to assess the
regenerative power of the cells collected. These assays,
however, were (and still are) difficult to perform in a
standardized manner. Also, the cultures took 2 to 3
weeks to grow out and be read, making these assays
impractical for a graft quality measurement.
In the early 1990s, CD34 surface antigen testing of
cells by flow cytometry made it possible to predict
engraftment potential. As a result, the term stem cell
became suspect for these products,because the testing
found cells that could speed engraftment but did not
always find the earliest cells that assured long-term
hematopoietic engraftment.6 This led to use of the
term hematopoietic progenitor cell. The AABB7 and the
Foundation for the Accreditation of Cellular Therapy
(FACT) standards8 required that products be labeled
with their product name as well as with identifying
numbers or names. The FACT standards of the day
required that the word Human also be included in the
label. This led to quite complex and lengthy names,
such as “Human Peripheral Blood Hematopoietic
Progenitor Cells.” Although very descriptive, such long
names took up a lot of real estate on the label, espe-
cially if the font size was large enough to be readable.
Another problem was that different institutions had
different names for the same cell therapy products. It
was difficult to know whether products with similar
names met the same specifications or were collected
and stored in the same way. They needed a common
language.
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Circular of Information Product Names
A group of cell therapy leaders drawn from the
professional groups involved in writing standards for
the field met in 2001 to create a circular of information
for cell therapy products (published in 2002).
Although circulars of information had been previously
required by the standard-setting organizations, they
were quite variable in content and complexity. This
new group agreed that the basic elements should
include general descriptions of the products, their
common uses, and possible adverse consequences that
patients might experience, be observed for, and be
treated for, if necessary.
An updated Circular of Information for the Use of
Cell Therapy Products was published in 2005. It was
prepared jointly by the AABB,America’s Blood Centers
(ABC),American Association of Tissue Banks,American
Red Cross (ARC), American Society for Blood and
Marrow Transplantation, FACT, International Council
for Commonality in Blood Bank Automation (ICCBBA),
International Society for Cellular Therapy (ISCT), and
NMDP. In this document, the interested parties
accepted a simplified system of mutually agreed-upon
names, using the abbreviation HPC in place of
hematopoietic progenitor cells. The most commonly
collected and labeled products were given the names
HPC,Apheresis; HPC,Marrow; and HPC, Cord.
Stimulated peripheral blood did not merit a
separate product name, as it could only be collected by
apheresis procedures to get sufficient numbers for
transplantation. Because apheresis procedures could
not be used to collect marrow or cord blood, the group
reasoned that it was sufficient to use HPC,Apheresis as
the name of this product. Similarly, Human Umbilical
Cord Blood Hematopoietic Progenitor Cells was
considered too long a name for the label; HPC, Cord
was accepted.
This kind of agreement was timely because cord
blood banking and transplantation opened a whole
new area of cell therapy.9 Many features were similar
to more traditional blood banking, such as the need to
perform screening and infectious disease testing on
unrelated, anonymous donors and mothers before the
units could be banked and offered for general use. But
the old system of using name,hospital number, or both
was clearly inadequate, especially inasmuch as large
allogeneic, public cord blood banks were being set up
worldwide.10 Establishing agreed-upon product names
was a very good direction for a field already exploding
with new uses for cell therapies and new cell products
to be named. For example, doses of cells rich in
lymphocytes from the allogeneic bone marrow donor
were found to be useful after transplantation to treat
leukemia relapse and facilitate more complete
engraftment of the donor immune system in the
recipient.11 These collections targeted T lymphocytes,
not HPC. Should they be named Donor-specific
Lymphocyte Infusions (DLI), Therapeutic T Cells, or
Therapeutic Leukocyte Infusions, because one could
not guarantee that all the cells collected were T
lymphocytes? Should the name reflect the content of
the collection or the intent or probable use of the
collection? This debate continues.
FDA Regulation and Guidance
As the field of cell therapy and transplantation
progressed from a few research centers to much larger
operations,potentially affecting more of the population
of the United States, the FDA became increasingly
involved. In May 2005, it established labeling regula-
tions pertaining to cell therapy products defined in 21
CFR §1271 and covered by the Public Health Service
Act (PHSA) in §361.12 21 CFR §1271(c) requires that
human cells, tissues, and cellular and tissue-based
products (HCT/P) have:
• a distinct identification code, e.g., alphanumeric,
that relates to the donor and all associated
records that assist in tracking the product from
the donor to the recipient (except in the case of
autologous or directed family donations, cannot
be the person’s name, Social Security Number, or
medical records number),
• a description of the type of HCT/P,
• an expiration date, if any, and
• warnings, if applicable, as defined in
– 21 CFR §1271.60. If the donor has not had
evaluation for infectious disease completed, the
product must be held or shipped in quarantine.
If the product is released for urgent medical
need before the evaluation of the donor can be
completed, the product must be prominently
labeled with “NOT EVALUATED FOR INFEC-
TIOUS SUBSTANCES” and “WARNING: Advise
patient of communicable disease risks.”
– 21 CFR §1271.65. If an HCT/P is from an
ineligible donor, but is intended for use under
special circumstances, such as use in a first-
degree or second-degree blood relative;
reproductive cells or tissue from a reproductive
donor who knows and is known by the specific
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recipient;or there is an urgent medical need. In
this case the product must bear the Biohazard
legend and the statement: “WARNING: Advise
patient of communicable disease risks.”
The following information must accompany the
HCT/P either on the label or in accompanying
information:
• name and address of the establishment that
determined that the HCT/P meets release criteria
and makes the HCT/P available for distribution,
• storage temperature,
• other warnings,where appropriate, and
• instructions for use when related to the
prevention of the introduction, transmission, or
spread of communicable disease.
ISBT 128 Bar-coded Product Labels and
Unique Identifiers
Although there are any number of possible
solutions to the internationally readable bar-coded
label requirements, one system under consideration in
the United States is already internationally accepted.
TheWorking Party on Automation and Data Processing
of the International Society of Blood Transfusion (ISBT)
proposed the ISBT 128 system in 1989. The AABB,ABC,
and ARC established the Council for Commonality in
Blood Banking Automation (CCBBA) to implement
ISBT 128 in the United States. The standard,data identi-
fiers, and application specification were developed
between 1990 and 1994. In 1994, the ISBT council
approved the ISBT 128 application specification and
established the office for the ICCBBA from the CCBBA
to ensure that any new standard designed around code
128 would be maintained. In 1995, ICCBBA was
incorporated (not-for-profit) in Virginia. Facilities
collecting blood, HPC, and tissue and manufacturers of
equipment or software that use ISBT 128 are required
to register with ICCBBA, Inc. For further information,
visit the ICCBBA, Inc., Web site at http://www.
iccbba.com.
ISBT 128 specifies the following:
• use of a unique donation identifier worldwide,
• data structures for important information on the
product label,
• the assignment of product codes by ICCBBA,
• a data structure for software developers to
interface necessary input and output messages,
and
• a standard label format that ensures a consistent
layout of critical product information.
ISBT 128 has gained widespread acceptance. As of
2005, facilities in 40 countries on five continents and
44 worldwide vendors for software, bags, and labels
had registered with ICCBBA to use ISBT 128. The
number of registrants increases each year. Interna-
tional organizations, including the AABB, European
Plasma Fractionators Association, European Blood
Alliance, and FDA, have endorsed ISBT 128. In June
2000, the FDA issued a guidance document recognizing
ISBT 128 as an acceptable standard for uniform
labeling. Despite this acceptance, adoption of the
system has been slow with cost cited as the reason.
However, now that it is being accepted and slowly put
into use around the country, it seems unlikely that
hospitals and centers would be anxious to adopt
multiple systems to take care of each cell and tissue
type.
Minimally Manipulated Products
The cell therapy minimally manipulated,
homologous-use cell preparations are described in
PHSA §361, and the regulations for these products are
found in 21 CFR §1270 and §1271. A simple, general
bar-coding system as described in a previous section
for minimally manipulated, homologous-use products
covered under PHSA §361 has been constructed by a
coalition of industry groups and presented to the FDA
as an official recommendation. The Office of Cell and
Gene Therapy (OCGT) at the FDA Center for Biologic
Evaluation and Research has considered the naming of
the minimally manipulated products, and the issue is as
yet undecided. The FDA has asked for public comment
on whether NDC codes, the same type of bar codes as
those required for pharmaceuticals and highly
processed cell products, are appropriate considering
that bar coding is currently required.
More Than Minimally Manipulated Products
What happens if the cell therapy products are
more complex in their preparation and production and
are covered under PHSA §351? They are covered in
regulations by 21 CFR §211 and §600. These more-
than-minimally manipulated products will be named by
a new plan devised especially for them. A naming plan
was devised and accepted by the Cellular Therapies
Working Group from the American Medical Association
and the OCGT. These products will be covered under
PHSA §351,13 meaning that these products must be
produced under full good manufacturing practices and
regulatory oversight.
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In this plan, the name of a product is created using
the following components to construct the name.
• Prefix: established by the United States Adopted
Names council to provide uniqueness
• Infix:may be derived from the following:
– manipulation
 -gen = transduced;
 -pul = pulsed with peptide or other agent;
 -fus = fused with peptide,cells,or other agent
– cell type, e.g.,
 -myo = myoblast
 -isle = islet cell
 -den = dendritic cell
• Suffix
– -cel (stem for cell therapies); used for all cell
therapies
– -imut (stem for immunomodulators); used for
all noncellular cell therapy products, which
include cell lysates, peptides, or proteins used
for cancer vaccines. Substems for these
vaccines are as follows:
 -lisimut (stem for cell lysates)
 -pepimut (stem for peptides)
 -protimut (stem for protein)
• Qualifiers: letter after hyphen at the end of name
– T = autologous
– L = allogeneic
– X = xenogenic
Following these guidelines, a product name would
be composed of a prefix, infix 1, infix 2, and a suffix
with a qualifier. For example, the name for a neuronal
stem cell would be derived from neuro (infix for the
cell), prog (second infix for progenitor), and cel (stem
of the product) followed by a qualifier letter T, L, or X
to indicate the source. Similarly, a dendritic cell that
has been fused with a tumor cell would be a fusdencel.
The remainder of this plan, including more
examples, can be found at Web site http://www.
ama-assn.org/ama/pub/category/15395.html.
View of the Future
The starting point to solve the current label puzzle
is the consensus established by the two circulars of
information from the professional societies. A label
design task group is now meeting to construct ISBT
128 bar-coded labels for cell therapy products
currently covered by 21 CFR §1271 and by professional
standards. This is a critically important task because
there are no standard label formats and no widely
accepted label designs although these are required by
regulation. An international standard is desperately
needed. For example, one-half of all of the allogeneic
bone marrow transplantation products from unrelated
donors in Australia come from international sources as
reported by Dr. Kerry Atkinson at the 2006 ISCT
meeting in Berlin.
In the United States, if industry does not agree on
and present bar codes and labels to the FDA, the FDA
will provide an issued bar code for only those products
that are nationally recognized; these will be structured
the same as the bar codes issued for pharmaceutical
products. This action will limit the computerized
control of both domestic and international products
that might be required for hard-to-match patients.
Because blood transfusion services are accepting ISBT
128 coding for transfusion components, hospital
computer systems are being modified to accept this
electronic language internationally.
Cell therapy laboratories are rightfully concerned
about the expense of installing a new labeling system
when they have not been required to have one in the
past. This is a positive aspect because, to date, large
sums of money have not been spent on competing and
incompatible systems. By extending the system that
the transfusion service will have in place, the
regulatory requirements can be met with a system that
may have extended utility. It is clear that a unique,
machine-readable as well as eye-readable system will
have to be put in place. Using this opportunity to
install an internationally recognized system will make
future labeling steps more useful in identifying and
tracking products through the shipping process,
integrating the cell therapy products into patient
charting, and promoting the patient’s safety by using
the checks and balances available to assure certainty of
identification that can eventually be extended to both
cell therapy product and patient.
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Free Classified Ads and Announcements
Immunohematology will publish classified ads and announcements (SBB schools, meetings, symposia, etc.)
without charge. Deadlines for receipt of these items are as follows:
Deadlines
1st week in January for the March issue
1st week in April for the June issue
1st week in July for the September issue
1st week in October for the December issue
E-mail or fax these items to Cindy Flickinger,Managing Editor, at (215) 451-2538 or flickingerc@usa.redcross.org.
